Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Yoo Jin ChoiYoonhyeong ByunJae-Seung KangHyeong Seok KimYoungmin HanHyeong Seok KimWooil KwonDo Youn OhWoo Hyun PaikSang Hyub LeeJi-Kon RyuYong-Tae KimKyoung-Bun LeeHaeryoung KimEui Kyu ChieJin-Young JangPublished in: Gut and liver (2021)
FOLFIRINOX provided more clinical and oncological benefit than gemcitabine, with significantly higher overall survival and lower cumulative recurrence rates in BRPC. However, since FOLFIRINOX causes more adverse effects, the regimen should be individualized based on patient's general condition and clinical status.